share_log

Novavax | 8-K: R&D President Filip Dubovsky Resigns

Novavax | 8-K: R&D President Filip Dubovsky Resigns

諾瓦瓦克斯醫藥 | 8-K：研發總裁Filip Dubovsky辭職
美股sec公告 ·  05/24 04:12
牛牛AI助理已提取核心訊息
On May 20, 2024, Novavax, Inc. announced the retirement of Filip Dubovsky as President of Research and Development, effective June 30, 2024. Dubovsky will continue to provide consulting services to Novavax for 12 months post-retirement under a consulting agreement. The agreement stipulates a monthly consulting fee of $15,000 and payment of COBRA premiums for up to 11 months. Dubovsky's equity awards will vest during the consulting period, and any unexercised stock options will remain exercisable for 90 days after the consulting period ends. The agreement allows for termination by either party with 30 days' notice. The terms of Dubovsky's non-competition and non-solicitation covenants will begin post-retirement. Details of the consulting agreement will be included in Novavax's Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.
On May 20, 2024, Novavax, Inc. announced the retirement of Filip Dubovsky as President of Research and Development, effective June 30, 2024. Dubovsky will continue to provide consulting services to Novavax for 12 months post-retirement under a consulting agreement. The agreement stipulates a monthly consulting fee of $15,000 and payment of COBRA premiums for up to 11 months. Dubovsky's equity awards will vest during the consulting period, and any unexercised stock options will remain exercisable for 90 days after the consulting period ends. The agreement allows for termination by either party with 30 days' notice. The terms of Dubovsky's non-competition and non-solicitation covenants will begin post-retirement. Details of the consulting agreement will be included in Novavax's Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.
2024年5月20日，Novavax, Inc.宣佈菲利普·杜波夫斯基退休研發總裁一職，自2024年6月30日起生效。根據諮詢協議，杜波夫斯基將在退休後的12個月內繼續向Novavax提供諮詢服務。該協議規定每月諮詢費爲15,000美元，並支付長達11個月的COBRA保費。杜波夫斯基的股權獎勵將在諮詢期內歸屬，任何未行使的股票期權將在諮詢期結束後的90天內繼續行使。該協議允許任何一方在提前30天通知的情況下終止。杜波夫斯基的禁止競爭和不招攬契約的條款將在退休後生效。諮詢協議的詳細信息將包含在Novavax截至2024年6月30日的季度10-Q表季度報告中。
2024年5月20日，Novavax, Inc.宣佈菲利普·杜波夫斯基退休研發總裁一職，自2024年6月30日起生效。根據諮詢協議，杜波夫斯基將在退休後的12個月內繼續向Novavax提供諮詢服務。該協議規定每月諮詢費爲15,000美元，並支付長達11個月的COBRA保費。杜波夫斯基的股權獎勵將在諮詢期內歸屬，任何未行使的股票期權將在諮詢期結束後的90天內繼續行使。該協議允許任何一方在提前30天通知的情況下終止。杜波夫斯基的禁止競爭和不招攬契約的條款將在退休後生效。諮詢協議的詳細信息將包含在Novavax截至2024年6月30日的季度10-Q表季度報告中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。